Last week, our Research Directors, Siobhan Davies and Lindsay Widger, landed back in the UK from the ESMO Congress 2023 in Madrid.
The conference brought together likeminded passionate professionals in oncology to discuss and digest the very latest developments.
ESMO Congress 2023 represented a shift forward in cancer care, with some papers even getting a standing ovation…
- Delivering ‘the best ever lung ESMO programme’
- Featuring two bladder cancer papers in the plenary/presidential symposiums
- Resulting in ~10 concomitant NEJM publications
Our key picks discussed at ESMO 2023
Our Oncology team, Lindsay Widger, Siobhan Davies, Paula Coyle and Tessa Rothwell, have identified their top five takeouts from ESMO 2023.
- ADCs continue to shine and show no sign of stopping with new combinations and next generation agents showing promising data.
- However, with the rise of ADCs comes a new wave of toxicities. There is a need for education (for HCPs and patients), close monitoring and better prediction.
- Rivalling docetaxel in 2L advanced NSCLC (after chemo-IO) proves to be tricky – personalised/targeted approaches are likely to be required.
- Moving towards a more complex treatment algorithm for EGFR+ advanced NSCLC with amivantamab combinations taking centre stage.
- The murky realm of IO in resectable NSCLC remains murky – more positive trials with perioperative IO were reported, but the question that remains is “who needs the adjuvant portion?”.
Take a look at our article to gain a deeper understanding on these topics.
Click here to see our reflections
Please contact our oncology team to discuss how we can best support you and share our insights with you.
Lindsay Widger – l.widger@beyondblueinsight.com
Siobhan Davies – s.davies@beyondblueinsight.com
Paula Coyle – p.coyle@beyondblueinsight.com
Tessa Rothwell – t.rothwell@beyondblueinsight.com